Mirror Images of Invisibility-the Hispanic Journalist: How Does the Disproportionate Ratio of Local Hispanic News Anchors and Reporters Impact San Antonio Hispanics?

The U.S. 2000 Census reveals San Antonio\u27s 671,394 Hispanic or Latino population is 58.7 percent of the city\u27s 1.14 million people. This statistic contrasts nationwide to 12.5 percent or 35.3 million Hispanic or Latino people. San Antonio, ninth-largest U.S. city in total population, compares to two other Texas cities, Houston ranking fourth-largest and Dallas eighth-largest. San Antonio, fifth-largest city in Hispanic population on the U.S. Census chart of Ten Largest Places in Total Population and in Hispanic Population, outnumbers Dallas, listed eighth-largest in Hispanic population. Only Houston, remaining the fourth-largest Texas city, outranks San Antonio in Hispanic population. San Antonio Hispanics, who watch the mainstream local newscasts, will notice the ratio of Hispanic news anchors and reporters appears disproportionate to the area demographics, giving the above facts extreme importance. When a city, ranked ninth in the nation and nearly 60 percent Hispanic, lacks comparable representation on its local news, the situation cries for a response because of the seemingly inequitable situation. The question of whether or not the ratio of Hispanic news anchors and reporters represents the Hispanic population becomes an interesting one to explore because of the multifaceted social and cultural issues presented in this circumstance. This study explores some of the impacts that result from these social and cultural issues

Estrés oxidativo y capacidad antioxidante en deportistas con dieta rica en antioxidantes con zarzamora (Rubus sp.)

Objetivo. Identificar el comportamiento del Estrés Oxidativo (EO) en atletas con y sin la ingesta de dieta rica en antioxidantes durante el periodo competitivo. Métodos. Se evaluaron a 14 atletas de alto rendimiento del equipo de balonmano, quienes fueron distribuidos 7 en un grupo experimental y 7 en un grupo control (con y sin ingesta de zarzamora, respectivamente). El consumo de la bebida de zarzamora o placebo para ambos grupos, fue de una dosis diaria durante 15 días (7 días en la etapa de pre competencia, 7 días durante el periodo de competencia y una dosis 24h después de finalizar la competencia). Se cuantificó el EO (i.e. prueba d-ROMs, unidades Cornelli, U. Cor.) y la capacidad total antioxidante (CTA) en plasma (i.e. prueba PAT, unidades Carratelli, U. Carr.), en 4 momentos: (1) reposo (1 semana previa a competencia, antes del suministro de bebida); (2) pre competencia (una semana antes de la competencia); (3) al final de competencia y (4) a las 24 h después de la competencia. Resultados. En el grupo experimental, el EO disminuyó de manera significativa (p = .018) al comparar la toma en reposo con la toma previa a la competencia después de 7 días de la ingesta de la dieta rica en antioxidantes. El grupo control presentó aumentos significativos de la CTA en la toma previa a competencia (p = .028) así como al final de la misma (p = .046), con respecto a la toma en reposo. Conclusión. El EO se incrementa después de la competencia y estimula la CTA. La ingesta de la dieta rica en antioxidantes es favorable en el entrenamiento previo a la competencia ya que promueve la regulación del EO, disminuyendo los valores del mismo.Objective. Identify Oxidative Stress (OS) behavior in athletes with and without the intake of an antioxidant-rich diet during a competitive period. Methods.14 high-performance athletes of handball team were evaluated. Two groups were established: 7 in an experimental group (blackberry intake) and 7 in a control group (with and without the intake of blackberry, respectively). The intake of blackberry beverage or placebo for both groups was a daily dose for 15 days (7 days in the pre-competition stage, 7 days during the competition period and a dose 24h after the end of the competition). OS (i.e. d-ROMs test, Cornelli units, U.Cor.) and the Total Antioxidant Capacity (TAC) (i.e. PAT test, Carratelli units, U. Carr.) on plasma, were quantified at 4 moments: (1) resting (1 week before the competition, before the beverage intake); (2) pre competition (one week before the competition); (3) at the end of the competition; and (4) 24 hours after the competition. Results. On the experimental group, OS was significantly reduced (p =.018) comparing resting takes with the pre-competition, after 7 days of the antioxidant-rich diet. The control group had a significant rise on TAC presented in precompetition (p =.028) as well as at end of competition (p =.046) compared to the resting take. Conclusion. The OS rises after competition and stimulates the TAC. The intake of an antioxidant-rich diet is helpful on pre competition training since it promotes the regulation of OS, diminishing its levels.Objetivo. Identificar o comportamento do estresse oxidativo (EO) em atletas com e sem a ingestão de dieta rica em antioxidantes durante o período competitivo. Métodos. Foram avaliadas 14 atletas de alto rendimento da equipe de handebol, que foram distribuídos em 7 num grupo experimental e 7 num grupo de controlo (com e sem ingestão de amora, respectivamente). O consumo da amora bebida ou placebo em ambos os grupos era uma dose diária durante 15 dias (7 dias no pré competição, 7 dias durante a competição e uma dose 24 horas depois de terminar a competição). O EO foi quantificado (i.e. prova d-ROMs, unidades Cornelli, U. Cor.) e a capacidade antioxidante total (CAT) no plasma (isto é, teste de PAT, unidades Carratelli, U. Carr.) em 4 fases: (1) repouso (uma semana antes da competição antes do fornecimento de bebida); (2) pré-competição (uma semana antes da competição); (3) no fim da competição e (4) às 24 h após a competição. Resultados. No grupo experimental, o EO diminuiu significativamente (p = 0,018) comparando a toma em repouso com a toma anterior à competição após 7 dias de ingestão da dieta rica em antioxidantes. O grupo de controlo teve aumentos significativos no CAT na toma previa à competição (p = .028) e no final da mesma (p = .046), com respeito à toma em repouso. onclusão. O EO aumenta após da competição e estimula o CAT. A ingestão de dieta rica em antioxidantes é favorável no treinamento pré-competição, uma vez que promove a regulação da EO, diminuindo os valores do mesmo

ASPECTOS CONTROVERTIDOS DOS ACORDOS DE LENIÊNCIA NO DIREITO BRASILEIRO

O artigo versa sobre diversas questões relativas ao acordo de leniência previsto na Lei n. 12.529/2011 e Lei n. 12.846/2013. Discorre-se sobre sua origem, seu desenvolvimento no Brasil, seus requisitos legais, sobre sua relação com a responsabilidade empresarial e individual, sobre os conflitos de interesse no âmbito da organização empresarial, sobre questões processuais penais, incluído a pertinência ou não da participação do Ministério Público na celebração de acordo de leniência, além de seus possíveis reflexos no âmbito da improbidade administrativa

The burden of mental disorders, substance use disorders and self-harm among young people in Europe, 1990–2019: Findings from the Global Burden of Disease Study 2019

Summary Background Mental health is a public health issue for European young people, with great heterogeneity in resource allocation. Representative population-based studies are needed. The Global Burden of Disease (GBD) Study 2019 provides internationally comparable information on trends in the health status of populations and changes in the leading causes of disease burden over time. Methods Prevalence, incidence, Years Lived with Disability (YLDs) and Years of Life Lost (YLLs) from mental disorders (MDs), substance use disorders (SUDs) and self-harm were estimated for young people aged 10-24 years in 31 European countries. Rates per 100,000 population, percentage changes in 1990-2019, 95% Uncertainty Intervals (UIs), and correlations with Sociodemographic Index (SDI), were estimated. Findings In 2019, rates per 100,000 population were 16,983 (95% UI 12,823 – 21,630) for MDs, 3,891 (3,020 - 4,905) for SUDs, and 89·1 (63·8 - 123·1) for self-harm. In terms of disability, anxiety contributed to 647·3 (432–912·3) YLDs, while in terms of premature death, self-harm contributed to 319·6 (248·9–412·8) YLLs, per 100,000 population. Over the 30 years studied, YLDs increased in eating disorders (14·9%;9·4-20·1) and drug use disorders (16·9%;8·9-26·3), and decreased in idiopathic developmental intellectual disability (–29·1%;23·8-38·5). YLLs decreased in self-harm (–27·9%;38·3-18·7). Variations were found by sex, age-group and country. The burden of SUDs and self-harm was higher in countries with lower SDI, MDs were associated with SUDs. Interpretation Mental health conditions represent an important burden among young people living in Europe. National policies should strengthen mental health, with a specific focus on young people.publishedVersio

The burden of mental disorders, substance use disorders and self-harm among young people in Europe, 1990-2019 : Findings from the Global Burden of Disease Study 2019

Background Mental health is a public health issue for European young people, with great heterogeneity in resource allocation. Representative population-based studies are needed. The Global Burden of Disease (GBD) Study 2019 provides internationally comparable information on trends in the health status of populations and changes in the leading causes of disease burden over time. Methods Prevalence, incidence, Years Lived with Disability (YLDs) and Years of Life Lost (YLLs) from mental disorders (MDs), substance use disorders (SUDs) and self-harm were estimated for young people aged 10-24 years in 31 European countries. Rates per 100,000 population, percentage changes in 1990-2019, 95% Uncertainty Intervals (UIs), and correlations with Sociodemographic Index (SDI), were estimated. Findings In 2019, rates per 100,000 population were 16,983 (95% UI 12,823 - 21,630) for MDs, 3,891 (3,020 4,905) for SUDs, and 89.1 (63.8 - 123.1) for self-harm. In terms of disability, anxiety contributed to 647.3 (432 -912.3) YLDs, while in terms of premature death, self-harm contributed to 319.6 (248.9-412.8) YLLs, per 100,000 population. Over the 30 years studied, YLDs increased in eating disorders (14.9%;9.4-20.1) and drug use disorders (16.9%;8.9-26.3), and decreased in idiopathic developmental intellectual disability (-29.1%;23.8-38.5). YLLs decreased in self-harm (-27.9%;38.3-18.7). Variations were found by sex, age-group and country. The burden of SUDs and self-harm was higher in countries with lower SDI, MDs were associated with SUDs. Interpretation Mental health conditions represent an important burden among young people living in Europe. National policies should strengthen mental health, with a specific focus on young people. Funding The Bill and Melinda Gates Foundation Copyright (C) 2022 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)Peer reviewe

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049

Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults

Background Underweight and obesity are associated with adverse health outcomes throughout the life course. We estimated the individual and combined prevalence of underweight or thinness and obesity, and their changes, from 1990 to 2022 for adults and school-aged children and adolescents in 200 countries and territories. Methods We used data from 3663 population-based studies with 222 million participants that measured height and weight in representative samples of the general population. We used a Bayesian hierarchical model to estimate trends in the prevalence of different BMI categories, separately for adults (age ≥20 years) and school-aged children and adolescents (age 5–19 years), from 1990 to 2022 for 200 countries and territories. For adults, we report the individual and combined prevalence of underweight (BMI &lt;18·5 kg/m2) and obesity (BMI ≥30 kg/m2). For school&#x2;aged children and adolescents, we report thinness (BMI &lt;2 SD below the median of the WHO growth reference) and obesity (BMI &gt;2 SD above the median). Findings From 1990 to 2022, the combined prevalence of underweight and obesity in adults decreased in 11 countries (6%) for women and 17 (9%) for men with a posterior probability of at least 0·80 that the observed changes were true decreases. The combined prevalence increased in 162 countries (81%) for women and 140 countries (70%) for men with a posterior probability of at least 0·80. In 2022, the combined prevalence of underweight and obesity was highest in island nations in the Caribbean and Polynesia and Micronesia, and countries in the Middle East and north Africa. Obesity prevalence was higher than underweight with posterior probability of at least 0·80 in 177 countries (89%) for women and 145 (73%) for men in 2022, whereas the converse was true in 16 countries (8%) for women, and 39 (20%) for men. From 1990 to 2022, the combined prevalence of thinness and obesity decreased among girls in five countries (3%) and among boys in 15 countries (8%) with a posterior probability of at least 0·80, and increased among girls in 140 countries (70%) and boys in 137 countries (69%) with a posterior probability of at least 0·80. The countries with highest combined prevalence of thinness and obesity in school-aged children and adolescents in 2022 were in Polynesia and Micronesia and the Caribbean for both sexes, and Chile and Qatar for boys. Combined prevalence was also high in some countries in south Asia, such as India and Pakistan, where thinness remained prevalent despite having declined. In 2022, obesity in school-aged children and adolescents was more prevalent than thinness with a posterior probability of at least 0·80 among girls in 133 countries (67%) and boys in 125 countries (63%), whereas the converse was true in 35 countries (18%) and 42 countries (21%), respectively. In almost all countries for both adults and school-aged children and adolescents, the increases in double burden were driven by increases in obesity, and decreases in double burden by declining underweight or thinness. Interpretation The combined burden of underweight and obesity has increased in most countries, driven by an increase in obesity, while underweight and thinness remain prevalent in south Asia and parts of Africa. A healthy nutrition transition that enhances access to nutritious foods is needed to address the remaining burden of underweight while curbing and reversing the increase in obesit

VIII Encuentro de Docentes e Investigadores en Historia del Diseño, la Arquitectura y la Ciudad

Acta de congresoLa conmemoración de los cien años de la Reforma Universitaria de 1918 se presentó como una ocasión propicia para debatir el rol de la historia, la teoría y la crítica en la formación y en la práctica profesional de diseñadores, arquitectos y urbanistas. En ese marco el VIII Encuentro de Docentes e Investigadores en Historia del Diseño, la Arquitectura y la Ciudad constituyó un espacio de intercambio y reflexión cuya realización ha sido posible gracias a la colaboración entre Facultades de Arquitectura, Urbanismo y Diseño de la Universidad Nacional y la Facultad de Arquitectura de la Universidad Católica de Córdoba, contando además con la activa participación de mayoría de las Facultades, Centros e Institutos de Historia de la Arquitectura del país y la región. Orientado en su convocatoria tanto a docentes como a estudiantes de Arquitectura y Diseño Industrial de todos los niveles de la FAUD-UNC promovió el debate de ideas a partir de experiencias concretas en instancias tales como mesas temáticas de carácter interdisciplinario, que adoptaron la modalidad de presentación de ponencias, entre otras actividades. En el ámbito de VIII Encuentro, desarrollado en la sede Ciudad Universitaria de Córdoba, se desplegaron numerosas posiciones sobre la enseñanza, la investigación y la formación en historia, teoría y crítica del diseño, la arquitectura y la ciudad; sumándose el aporte realizado a través de sus respectivas conferencias de Ana Clarisa Agüero, Bibiana Cicutti, Fernando Aliata y Alberto Petrina. El conjunto de ponencias que se publican en este Repositorio de la UNC son el resultado de dos intensas jornadas de exposiciones, cuyos contenidos han posibilitado actualizar viejos dilemas y promover nuevos debates. El evento recibió el apoyo de las autoridades de la FAUD-UNC, en especial de la Secretaría de Investigación y de la Biblioteca de nuestra casa, como así también de la Facultad de Arquitectura de la UCC; va para todos ellos un especial agradecimiento

Early mobilisation in critically ill COVID-19 patients: a subanalysis of the ESICM-initiated UNITE-COVID observational study

Background Early mobilisation (EM) is an intervention that may improve the outcome of critically ill patients. There is limited data on EM in COVID-19 patients and its use during the first pandemic wave. Methods This is a pre-planned subanalysis of the ESICM UNITE-COVID, an international multicenter observational study involving critically ill COVID-19 patients in the ICU between February 15th and May 15th, 2020. We analysed variables associated with the initiation of EM (within 72 h of ICU admission) and explored the impact of EM on mortality, ICU and hospital length of stay, as well as discharge location. Statistical analyses were done using (generalised) linear mixed-effect models and ANOVAs. Results Mobilisation data from 4190 patients from 280 ICUs in 45 countries were analysed. 1114 (26.6%) of these patients received mobilisation within 72 h after ICU admission; 3076 (73.4%) did not. In our analysis of factors associated with EM, mechanical ventilation at admission (OR 0.29; 95% CI 0.25, 0.35; p = 0.001), higher age (OR 0.99; 95% CI 0.98, 1.00; p ≤ 0.001), pre-existing asthma (OR 0.84; 95% CI 0.73, 0.98; p = 0.028), and pre-existing kidney disease (OR 0.84; 95% CI 0.71, 0.99; p = 0.036) were negatively associated with the initiation of EM. EM was associated with a higher chance of being discharged home (OR 1.31; 95% CI 1.08, 1.58; p = 0.007) but was not associated with length of stay in ICU (adj. difference 0.91 days; 95% CI − 0.47, 1.37, p = 0.34) and hospital (adj. difference 1.4 days; 95% CI − 0.62, 2.35, p = 0.24) or mortality (OR 0.88; 95% CI 0.7, 1.09, p = 0.24) when adjusted for covariates. Conclusions Our findings demonstrate that a quarter of COVID-19 patients received EM. There was no association found between EM in COVID-19 patients' ICU and hospital length of stay or mortality. However, EM in COVID-19 patients was associated with increased odds of being discharged home rather than to a care facility. Trial registration ClinicalTrials.gov: NCT04836065 (retrospectively registered April 8th 2021)